"What" Series

What is the difference between toxoids and antitoxins?

19 April 2024
2 min read

Toxoids and antitoxins are two different types of biological products that play roles in the prevention and treatment of certain diseases caused by toxins produced by bacteria, but they differ in their sources, preparation methods, and mechanisms of action.

Toxoids: 

Toxoids are usually made by treating bacterial exotoxins with chemical or physical methods. The treated toxins lose their original toxicity but retain their immunogenicity. For instance, the diphtheria toxoid is obtained by treating the exotoxin produced by the diphtheria bacillus with formaldehyde, which can stimulate the human body to produce an immune response against the diphtheria toxin. Toxoids are used for vaccination, giving recipients immunity against specific diseases through active artificial immunization.

Antitoxins: 

Antitoxins are antibodies specific to certain toxins and are typically derived from animals, such as horses or sheep, that have been infected with the toxin-producing pathogen and have mounted an immune response. Antitoxins can directly neutralize the toxic effects of the corresponding toxin and are used for the treatment of existing toxin poisoning, constituting passive immunity. Antitoxin serum can be obtained by injecting the toxin into an animal's body, causing it to produce an immune response and yield a serum containing specific antitoxins, which is then extracted and purified for therapeutic use.

In summary, toxoids are treated toxins used for preventative immunity, whereas antitoxins are specific antibodies used for the treatment of existing toxin poisoning. Toxoids create long-term immune protection by activating the immune system, while antitoxins provide immediate passive immunity.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Promising Outcomes for Neurona's NRTX-1001 in Resistant Epilepsy Revealed at 2024 AAN
Latest Hotspot
3 min read
Promising Outcomes for Neurona's NRTX-1001 in Resistant Epilepsy Revealed at 2024 AAN
19 April 2024
Neurona Therapeutics Reports Encouraging Results from Its NRTX-1001 Cell Therapy Study in Adults Suffering from Drug-resistant Focal Epilepsy at the 2024 AAN Annual Meeting.
Read →
An analysis of RXC-004's R&D progress and its clinical results presented at the 2024 AACR Annual Meeting
An analysis of RXC-004's R&D progress and its clinical results presented at the 2024 AACR Annual Meeting
18 April 2024
On April 5, 2024, the final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors were reported in 2024 AACR.
Read →
FDA Approves TransCode's Phase 1/2 Trial of TTX-MC138 for Advanced Solid Tumors
Latest Hotspot
3 min read
FDA Approves TransCode's Phase 1/2 Trial of TTX-MC138 for Advanced Solid Tumors
18 April 2024
TransCode Therapeutics has received FDA approval to start a Phase 1/2 clinical trial of TTX-MC138 in patients with advanced solid tumors.
Read →
Exploring the Latest Long Acting Injection Deal by Medincell: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest Long Acting Injection Deal by Medincell: A Guide to Rapidly Accessing Transaction Insights
18 April 2024
Medincell and AbbVie Partner to Co-Develop Six Long-Acting Injectables.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.